Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
() -- Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Administration for its drug selpercatinib, Retevmo, to treat adult and pediatric patients two years and older with locally advanced or metastatic solid tumors carrying a RET gene fusion, a genetic alteration that can dr